ACTG 330--SAFETY & PHARMACOKINETICS OF 1592U89 ALONE VS COMBINATION--PEDIATRIC

ACTG 330--安全

• 批准号: 6282271
• 负责人: RUSSEL B VAN DYKE
• 金额: $ 1.97万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6282271
• 关键词: AIDS therapy; antiAIDS agent; child (0-11); clinical research; clinical trial phase I; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; nucleoside analog; pediatric AIDS; pediatric pharmacology; pharmacokinetics

Zidovudine (ZDV), didanosine (ddI), stavudine (d4T), and lamivudine (3TC), are commonly used as single agents as well as in combination for treatment of HIV infection in children. Accumulating information suggests that combination therapy with two or more antiretroviral agents, however, may hold more promise than single-agent therapy in the long term management of HIV infection. In addition, as resistance to common medications occurs, it becomes increasingly important to investigate new medications that may be used to treat HIV-infected infants and children. 1592u89 is a nucleoside analog with activity against HIV similar to that of ZDV. In vitro studies of this new medication suggest that resistance to HIV is slow to emerge, and cross-resistance to other antiretrovirals rare; further 1592u89 may act synergistically to ddI, 3TC, and d4T. Early adult and pediatric studies demonstrated few toxicities with significant reduction in HIV viral load.

齐多夫定（ZDV）、去羟肌苷（ddI）、司他夫定（d4 T）和拉米夫定 (3TC)，通常用作单一药剂以及组合用于 治疗儿童艾滋病毒感染。积累的信息表明 然而，使用两种或多种抗逆转录病毒药物的联合治疗， 从长远来看， 艾滋病毒感染的管理。此外，作为抵抗共同 随着药物的出现，研究新的药物变得越来越重要。 可用于治疗感染艾滋病毒的婴儿和儿童的药物。 1592 u89是一种核苷类似物，其抗HIV的活性类似于 的ZDV。对这种新药的体外研究表明， 艾滋病毒的耐药性出现缓慢， 罕见;另外1592 u89可能与ddI、3 TC和d4 T协同作用。早期 成人和儿童研究表明，几乎没有毒性， 减少HIV病毒载量。